Latest On Coloplast A/S (CLPBF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2023-12-08 04:57 EST | Dividend | A dividend of $16 has been announced on Nov 30, -0001. It will be paid Dec 12, 2023 with an ex-dividend date of Dec 8, 2023. | Neutral |  |
| 2023-05-15 05:57 EST | Dividend | A dividend of $5 has been announced on May 11, 2023. It will be paid May 17, 2023 with an ex-dividend date of May 15, 2023. | Neutral | |
| 2023-05-11 13:16 EST | News | Coloplast ASB Non-GAAP EPS of DKK5.51, revenue of DKK6.06B | N/A | |
| 2023-02-03 15:22 EST | News | Coloplast ASB GAAP EPS of DKK5.31, revenue of DKK6.1B | N/A | |
| 2022-11-07 11:07 EST | News | Coloplast ASB GAAP EPS of $22.11, revenue of $6.05B beats by $3.04B | N/A | |
| 2022-08-17 10:22 EST | News | Coloplast ASB GAAP EPS of DKK6.06, revenue of DKK5.85B beats by DKK5.06B | N/A | |
| 2022-05-05 15:22 EST | News | Coloplast ASB GAAP EPS of DKK4.60, revenue of DKK5.5B | N/A | |
| 2022-01-25 22:10 EST | News | Coloplast ASB Non-GAAP EPS of DKK5.78, revenue of DKK5.17B | N/A | |
| 2021-12-03 04:58 EST | Dividend | A dividend of $14 has been announced on Nov 30, -0001. It will be paid Dec 7, 2021 with an ex-dividend date of Dec 3, 2021. | Neutral | |
| 2021-08-18 21:16 EST | News | Coloplast rises after reporting solid organic growth in FQ3 | N/A | |
| 2021-05-06 23:18 EST | News | Coloplast ASB reports FQ2 results | N/A | |
| 2021-03-18 23:23 EST | Analyst Rating | The Analyst Target Price has increased from $92.91 to $93.55. | Neutral | |
| 2021-03-18 06:22 EST | Analyst Rating | The Analyst Target Price has decreased from $93.09 to $92.91. | Sell | |
| 2021-03-17 14:30 EST | Analyst Rating | The Analyst Target Price has decreased from $93.29 to $93.09. | Sell | |
| 2021-03-16 22:45 EST | Analyst Rating | The Analyst Target Price has increased from $17.93 to $93.29. | Neutral | |
| 2021-03-13 04:59 EST | Analyst Rating | The Analyst Target Price has increased from $17.64 to $17.93. | Neutral | |
| 2021-03-12 05:15 EST | Analyst Rating | The Analyst Target Price has increased from $17.6 to $17.64. | Neutral | |
| 2021-03-11 01:22 EST | Analyst Rating | The Analyst Target Price has increased from $17.53 to $17.6. | Neutral | |
| 2021-03-10 05:27 EST | Analyst Rating | The Analyst Target Price has decreased from $17.64 to $17.53. | Sell | |
| 2021-03-09 01:11 EST | Analyst Rating | The Analyst Target Price has decreased from $17.7 to $17.64. | Sell | |
| 2021-03-06 01:17 EST | Analyst Rating | The Analyst Target Price has decreased from $17.82 to $17.7. | Sell | |
| 2021-03-05 12:52 EST | Analyst Rating | The Analyst Target Price has increased from $17.72 to $17.82. | Neutral | |
| 2021-03-04 12:58 EST | Analyst Rating | The Analyst Target Price has increased from $17.67 to $17.72. | Neutral | |
| 2021-03-03 01:49 EST | Analyst Rating | The Analyst Target Price has decreased from $17.73 to $17.67. | Sell | |
| 2021-03-02 01:29 EST | Analyst Rating | The Analyst Target Price has decreased from $17.83 to $17.73. | Sell | |
| 2021-02-27 01:15 EST | Analyst Rating | The Analyst Target Price has decreased from $17.85 to $17.83. | Sell | |
| 2021-02-26 12:51 EST | Analyst Rating | The Analyst Target Price has decreased from $18.04 to $17.85. | Sell | |
| 2021-02-26 05:11 EST | Analyst Rating | The Analyst Target Price has increased from $18.01 to $18.04. | Neutral | |
| 2021-02-24 22:42 EST | Analyst Rating | The Analyst Target Price has decreased from $18.03 to $18.01. | Sell | |
| 2021-02-24 05:24 EST | Analyst Rating | The Analyst Target Price has increased from $17.98 to $18.03. | Neutral | |
| 2021-02-23 01:18 EST | Analyst Rating | The Analyst Target Price has increased from $17.97 to $17.98. | Neutral | |
| 2021-02-22 00:57 EST | Analyst Rating | The Analyst Target Price has increased from $17.93 to $17.97. | Neutral | |
| 2021-02-20 01:11 EST | Analyst Rating | The Analyst Target Price has increased from $17.86 to $17.93. | Neutral | |
| 2021-02-19 12:53 EST | Analyst Rating | The Analyst Target Price has increased from $17.74 to $17.86. | Neutral | |
| 2021-02-19 01:13 EST | Analyst Rating | The Analyst Target Price has decreased from $17.81 to $17.74. | Sell | |
| 2021-02-18 00:59 EST | Analyst Rating | The Analyst Target Price has decreased from $17.86 to $17.81. | Sell | |
| 2021-02-17 01:11 EST | Analyst Rating | The Analyst Target Price has increased from $17.84 to $17.86. | Neutral | |
| 2021-02-16 12:49 EST | Analyst Rating | The Analyst Target Price has increased from $0 to $17.84. | Neutral | |
| 2021-02-04 09:12 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-03 13:19 EST | Earnings Estimate | An EPS average of $0.89 is estimated for the quarter ending on June 30, 2021. | Buy | |
| 2021-02-02 17:40 EST | News | Coloplast ASB reports Q1 results | N/A | |
| 2020-12-04 04:59 EST | Dividend | A dividend of $13 has been announced on Nov 30, -0001. It will be paid Dec 8, 2020 with an ex-dividend date of Dec 4, 2020. | Neutral | |
| 2020-11-26 22:34 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-08 01:39 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:58 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-06 05:08 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-05 05:26 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-04 13:42 EST | Earnings Estimate | An EPS average of $3.89 is estimated for the 2022 year. | Buy | |
| 2020-11-04 13:42 EST | Earnings Estimate | An EPS average of $0.78 is estimated for the quarter ending on March 31, 2021. | Buy | |
| 2020-11-03 15:16 EST | News | Coloplast ASB reports FQ4 results | N/A | |
About Coloplast A/S (CLPBF):
Coloplast A/S develops and markets intimate healthcare products and services worldwide. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as SpeediCath catheters that offer catheterization for both genders; Peristeen, an anal irrigation system for controlled emptying of the bowels; and Conveen Active urine bags. In addition, it provides wound care products, such as foam dressings under the Biatain brand and hydrocolloid dressing under the Comfeel brand, as well as skin care products, such as bathing and cleansing products, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Coloplast A/S was founded in 1954 and is headquartered in Humlebæk, Denmark.
General
- Name Coloplast A/S
- Symbol CLPBF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- Full Time Employees 12,500
- Last Split Factor5:1
- Last Split Date2012-12-19
- Fiscal Year EndSeptember
- Web URLhttp://www.coloplast.com
View More
Valuation
- Trailing PE 52.98
- Forward PE 40.82
- Price/Sales (Trailing 12 Mt.) 10.61
- Price/Book (Most Recent Quarter) 34.07
- Enterprise Value Revenue 1.75
- Enterprise Value EBITDA 5.07
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $3.66
- Next Year EPS Estimate $3.99
- Next Quarter EPS Estimate $0.81
- Profit Margin 23%
- Return on Assets 26%
- Return on Equity 76%
- Earnings Per Share $2.83
- Revenue Per Share $0
- Gross Profit 12.61 billion
- Quarterly Earnings Growth 0.6%
View More
ESG Rating
Highlights
- Market Capitalization 32.27 billion
- PEG Ratio 4
- Analyst Target Price $93.55
- Book Value Per Share $4.72
View More
Share Statistics
- Shares Outstanding 194.91 million
- Shares Float 130.46 million
- % Held by Insiders 3580%
- % Held by Institutions 19.86%
View More
Technicals
- Beta 0.08
- 52 Week High $175.18
- 52 Week Low $126.57
- 50 Day Moving Average 155.94
- 200 Day Moving Average 154.06
View More
Dividends
- Forward Annual Dividend Rate $3.89
- Forward Annual Dividend Yield 2.63%
- Payout Ratio 37%
- Dividend Date 2019-12-10
- ExDividend Date 2020-12-04
- Dividend Per Share $1.72
- Dividend Yield 0%
View More
Coloplast A/S (CLPBF) Dividend Calendar:
CLPBF's last dividend payment was made to shareholders on December 10, 2019.
Coloplast A/S pays out 37% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
Coloplast A/S (CLPBF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2021-02-02 | $4.74 billion | $5.33 | $5.45 | -2.2% |
| 2020-09-30 | 2020-12-31 | $4.59 billion | $0.87 | $5.02 | -82.57% |
| 2020-06-30 | 2020-09-30 | $4.42 billion | $0.77 | $4.92 | -84.4% |
| 2020-03-31 | 2020-06-30 | $N/A | $0.70 | $5.03 | -86% |
| 2019-12-31 | 2020-03-31 | $N/A | $0.74 | $5.01 | -85.25% |
| 2019-09-30 | 2019-12-31 | $674.18 million | $0.77 | $5.49 | -86% |
| 2019-06-30 | 2019-09-30 | $695.37 million | $0.54 | $5.16 | -89.46% |
| 2019-03-31 | 2019-06-30 | $661.06 million | $0.76 | $4.81 | -84.1% |
| 2018-12-31 | 2019-03-31 | $663.63 million | $0.72 | $4.71 | -84.75% |
| 2018-09-30 | 2018-12-31 | $657.44 million | $0.72 | $5.19 | -86.22% |
| 2018-06-30 | 2018-09-30 | $659.94 million | $0.76 | $4.78 | -84.08% |
| 2018-03-31 | 2018-06-30 | $666.36 million | $0.70 | $4.50 | -84.43% |
| 2017-12-31 | 2018-03-31 | $637.73 million | $0.71 | $4.54 | -84.28% |
| 2017-09-30 | 2017-12-31 | $627.38 million | $0.71 | $4.86 | -85.34% |
| 2017-06-30 | 2017-09-30 | $601.11 million | $0.75 | $4.79 | -84.24% |
| 2017-03-31 | 2017-06-30 | $555.9 million | $0.66 | $4.53 | -85.47% |
| 2016-12-31 | 2017-03-31 | $3.76 billion | $0.63 | $4.46 | -85.91% |
| 2016-09-30 | 2016-12-31 | $0.63 | $4.76 | -86.74% | |
| 2016-06-30 | 2016-09-30 | $0.30 | $4.58 | -93.45% | |
| 2016-03-31 | 2016-06-30 | $0.69 | $4.33 | -84.14% | |
| 2015-12-31 | 2016-03-31 | $0.66 | $4.30 | -84.68% | |
| 2015-09-30 | 2015-12-31 | $0.56 | $4.21 | -86.62% | |
| 2015-06-30 | 2015-09-30 | -$1.01 | $3.75 | -126.93% | |
| 2015-03-31 | 2015-06-30 | $0.50 | $3.92 | -87.35% | |
| 2014-12-31 | 2015-03-31 | $0.55 | $3.96 | -86.13% | |
| 2014-09-30 | 2014-12-31 | $0.61 | $3.99 | -84.76% | |
| 2014-06-30 | 2014-09-30 | $0.67 | $3.87 | -82.74% | |
| 2014-03-31 | 2014-06-30 | $0.68 | $0.65 | 4.25% | |
| 2013-12-31 | 2014-03-31 | -$0.02 | $0.65 | -102.55% | |
| 2013-09-30 | 2013-12-31 | $0.67 | |||
| 2013-06-30 | 2013-09-30 | $0.63 | |||
| 2013-03-31 | 2013-06-30 | $0.58 | |||
| 2012-12-31 | 2013-03-31 | $0.51 | |||
| 2012-09-30 | 2012-12-31 | $0.51 | |||
| 2012-06-30 | 2012-09-30 | $0.49 | |||
| 2012-03-31 | 2012-06-30 | $0.47 | |||
| 2011-12-31 | 2012-03-31 | $0.43 | |||
| 2011-09-30 | 2011-12-31 | $0.40 | |||
| 2011-06-30 | 2011-09-30 | $0.45 | |||
| 2011-03-31 | 2011-06-30 | $0.44 | |||
| 2010-12-31 | 2011-03-31 | $0.35 | |||
| 2010-09-30 | 2010-12-31 | $0.34 | |||
| 2010-06-30 | 2010-06-30 | $0.27 | |||
| 2010-03-31 | 2010-03-31 | $0.23 | |||
| 2009-12-31 | 2009-12-31 | $0.26 | |||
| 2009-09-30 | 2009-09-30 | $0.24 | |||
| 2009-06-30 | 2009-06-30 | $0.19 | |||
| 2009-03-31 | 2009-03-31 | $0.15 | |||
| 2008-12-31 | 2008-12-31 | $0.17 | |||
| 2008-09-30 | 2008-09-30 | $0.06 | |||
| 2008-06-30 | 2008-06-30 | $0.26 | |||
| 2008-03-31 | 2008-03-31 | $0.13 | |||
| 2007-12-31 | 2007-12-31 | $0.21 |
Coloplast A/S (CLPBF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Research Development | 186 million | 175 million | 182 million | N/A | N/A |
| Income Before Tax | 1.5 billion | 1.37 billion | 1.3 billion | N/A | N/A |
| Selling General Administrative | 1.5 billion | 1.52 billion | 1.43 billion | N/A | N/A |
| Gross Profit | 3.21 billion | 3.16 billion | 2.97 billion | N/A | N/A |
| Ebit | 1.7 billion | 1.59 billion | 1.58 billion | N/A | N/A |
| Operating Income | 1.54 billion | 1.47 billion | 1.37 billion | N/A | N/A |
| Income Tax Expense | 359 million | N/A | N/A | 299 million | 318 million |
| Total Revenue | 4.74 billion | 4.59 billion | 4.42 billion | N/A | N/A |
| Cost of Revenue | 1.53 billion | 1.43 billion | 1.45 billion | N/A | N/A |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | N/A |
| Net Income From Continuing Operations | 1.14 billion | 1.04 billion | 997 million | N/A | N/A |
| Net Income Applicable to Common Shares | 1.14 billion | N/A | N/A | 997 million | 1.07 billion |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 | Jan 31 2020 |
|---|---|---|---|---|---|
| Investments | -265 million | -176 million | N/A | N/A | N/A |
| Change to Liabilities | N/A | N/A | -63 million | -355 million | -355 million |
| Total Cash Flow from Investing Activities | N/A | N/A | -176 million | -246 million | -246 million |
| Net Borrowings | N/A | N/A | -151 million | -421 million | -421 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Operating Activities | N/A | N/A | 27 million | -62 million | -62 million |
| Change in Cash | -74 million | -90 million | N/A | N/A | N/A |
| Total Cash from Operating Activities | 1.69 billion | 1.43 billion | 1.43 billion | 611 million | 611 million |
| Depreciation | 215 million | 214 million | N/A | N/A | N/A |
| Other Cash Flow from Investing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Inventory | -154 million | -220 million | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | N/A | N/A | N/A | N/A | N/A |
| Change to Net Income | N/A | N/A | 218 million | 150 million | 150 million |
| Capital Expenditures | 241 million | 215 million | N/A | N/A | N/A |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Apr 30 2020 | Mar 31 2020 |
|---|---|---|---|---|---|
| Total Liabailities | 9.16 billion | 6.09 billion | 6.95 billion | N/A | N/A |
| Total Stockholder Equity | 5.77 billion | 7.41 billion | 6.36 billion | N/A | N/A |
| Other Current Liabilities | 3.01 billion | 9 million | 3 million | 6.36 billion | N/A |
| Total Assets | 14.93 billion | 13.5 billion | 13.32 billion | N/A | N/A |
| Common Stock | 216 million | N/A | N/A | 3 million | 216 million |
| Other Current Assets | N/A | N/A | N/A | 216 million | N/A |
| Retained Earnings | 5.88 billion | 4.74 billion | 6.42 billion | 6.42 billion | 6.66 billion |
| Other Liabilities | 903 million | N/A | N/A | 650 million | 646 million |
| Other Assets | 692 million | N/A | N/A | 604 million | 599 million |
| Cash | 435 million | 323 million | 411 million | 411 million | N/A |
| Total Current Liabilities | 7.78 billion | 4.98 billion | 5.92 billion | 5.92 billion | N/A |
| Other Stockholder Equity | -322 million | N/A | N/A | -278 million | -293 million |
| Property, Plant & Equipment | 4.05 billion | N/A | N/A | 3.8 billion | 3.76 billion |
| Total Current Assets | 6.64 billion | 6.49 billion | 6.49 billion | 6.49 billion | N/A |
| Long Term Investments | N/A | N/A | N/A | N/A | N/A |
| Net Tangible Assets | 2.25 billion | N/A | N/A | 3.94 billion | 4.13 billion |
| Short Term Investments | 257 million | 262 million | 262 million | 262 million | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A |
| Inventory | 2.23 billion | 2.23 billion | 2.12 billion | 2.12 billion | N/A |
| Accounts Payable | 563 million | 814 million | 623 million | 623 million | N/A |
Coloplast A/S (CLPBF) Chart:
Coloplast A/S (CLPBF) News:
Below you will find a list of latest news for Coloplast A/S (CLPBF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
Coloplast A/S (CLPBF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
Coloplast A/S (CLPBF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|---|---|---|
| 2011-08-29 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1294325/000101915511000398/0001019155-11-000398-index.htm |
| 2020-04-21 | F-6 | Registration of American Depository Receipt shares, not immediately effective | https://www.sec.gov/Archives/edgar/data/1294325/000101915520000072/0001019155-20-000072-index.htm |
| 2010-11-19 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1294325/000119380510002880/0001193805-10-002880-index.htm |
| 2010-12-10 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1294325/000119380510003016/0001193805-10-003016-index.htm |
| 2015-12-09 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1294325/000119380515002044/0001193805-15-002044-index.htm |
| 2017-09-29 | F-6 POS | Post-effective amendments for immediately effective filing | https://www.sec.gov/Archives/edgar/data/1294325/000119380517002620/0001193805-17-002620-index.htm |
| 2019-11-22 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1294325/000119380519001750/0001193805-19-001750-index.htm |
| 2014-11-12 | F-6EF | Registration of American Depository Receipt shares, immediately effective | https://www.sec.gov/Archives/edgar/data/1294325/000157104914006187/0001571049-14-006187-index.htm |
| 2020-05-05 | EFFECT | Notice of Effectiveness | https://www.sec.gov/Archives/edgar/data/1294325/999999999520001046/9999999995-20-001046-index.htm |
| 2008-08-21 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708036688/9999999997-08-036688-index.htm |
| 2008-08-12 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708037380/9999999997-08-037380-index.htm |
| 2008-08-19 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708037396/9999999997-08-037396-index.htm |
| 2008-09-03 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708037974/9999999997-08-037974-index.htm |
| 2008-09-02 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708037981/9999999997-08-037981-index.htm |
| 2008-09-15 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708039367/9999999997-08-039367-index.htm |
| 2008-12-02 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708046711/9999999997-08-046711-index.htm |
| 2008-12-05 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999708047544/9999999997-08-047544-index.htm |
| 2009-01-05 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709000567/9999999997-09-000567-index.htm |
| 2009-02-03 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709003991/9999999997-09-003991-index.htm |
| 2009-03-26 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709012262/9999999997-09-012262-index.htm |
| 2009-04-13 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709016755/9999999997-09-016755-index.htm |
| 2009-04-16 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709017299/9999999997-09-017299-index.htm |
| 2009-05-04 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709019324/9999999997-09-019324-index.htm |
| 2009-06-08 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709020788/9999999997-09-020788-index.htm |
| 2009-09-28 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709025368/9999999997-09-025368-index.htm |
| 2009-10-19 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709025961/9999999997-09-025961-index.htm |
| 2009-10-28 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709026127/9999999997-09-026127-index.htm |
| 2009-11-23 | ARS | Annual Report to Security Holders | https://www.sec.gov/Archives/edgar/data/1294325/999999999709026852/9999999997-09-026852-index.htm |
| 2009-12-17 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999709027460/9999999997-09-027460-index.htm |
| 2010-02-23 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710001213/9999999997-10-001213-index.htm |
| 2010-04-02 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710008009/9999999997-10-008009-index.htm |
| 2010-04-14 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710009069/9999999997-10-009069-index.htm |
| 2010-04-22 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710009497/9999999997-10-009497-index.htm |
| 2010-05-11 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710011052/9999999997-10-011052-index.htm |
| 2010-06-10 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710012816/9999999997-10-012816-index.htm |
| 2010-06-25 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710013866/9999999997-10-013866-index.htm |
| 2010-07-19 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710015555/9999999997-10-015555-index.htm |
| 2010-09-07 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710017790/9999999997-10-017790-index.htm |
| 2010-09-21 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710017996/9999999997-10-017996-index.htm |
| 2010-10-27 | SUPPL | Voluntary Supplemental Material by Foreign Issuers [Section 11(a)] | https://www.sec.gov/Archives/edgar/data/1294325/999999999710019126/9999999997-10-019126-index.htm |